Evan Wang
Stock Analyst at Guggenheim
(n/a)
# 4,712
Out of 5,122 analysts
6
Total ratings
n/a
Success rate
-59.54%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Evan Wang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SPRB Spruce Biosciences | Reiterates: Neutral | n/a | $83.49 | - | 3 | Dec 12, 2024 | |
| IVVD Invivyd | Upgrades: Buy | $9 | $1.88 | +378.72% | 1 | Apr 5, 2024 | |
| VALN Valneva SE | Maintains: Buy | $18 → $17 | $9.07 | +87.43% | 1 | Mar 22, 2024 | |
| MRNA Moderna | Initiates: Neutral | n/a | $42.20 | - | 1 | Apr 26, 2023 |
Spruce Biosciences
Dec 12, 2024
Reiterates: Neutral
Price Target: n/a
Current: $83.49
Upside: -
Invivyd
Apr 5, 2024
Upgrades: Buy
Price Target: $9
Current: $1.88
Upside: +378.72%
Valneva SE
Mar 22, 2024
Maintains: Buy
Price Target: $18 → $17
Current: $9.07
Upside: +87.43%
Moderna
Apr 26, 2023
Initiates: Neutral
Price Target: n/a
Current: $42.20
Upside: -